Health care is one of the most durable and structurally defensive corners of the equity market, which makes direct comparisons between leading sector funds especially relevant during periods of economic uncertainty and shifting interest-rate expectations. VHT and XLV are two of the most widely held vehicles for U.S. health care exposure, and they compete directly for the same investor dollar. Both are passively managed, market-cap-weighted funds with near-identical top holdings, yet they deliver meaningfully different diversification profiles. Understanding their structural differences is essential for investors deciding which fund better matches their risk tolerance and return objectives.
VHT seeks to track the MSCI US Investable Market Health Care 25/50 Index, a benchmark covering large, mid, and small U.S. companies classified within the health care sector under the Global Industry Classification Standard (GICS). With roughly 420 holdings, it provides one of the broadest pure-play health care exposures available. Its largest positions include LLY, JNJ, ABBV, MRK, and UNH, with additional weightings in TMO, AMGN, GILD, ABT, and PFE. The fund is passively managed using a replication and sampling approach, charges a 0.09% expense ratio, and launched in 2004. Its defining feature is depth: by reaching beyond the S&P 500, it captures smaller biotech, medical device, and health care services companies that large-cap-only funds exclude.
XLV tracks the Health Care Select Sector Index, which includes health care companies drawn from the S&P 500. With roughly 60 to 65 holdings, it offers concentrated exposure to the sector's largest, most liquid names. Its top holdings mirror VHT's leadership — LLY, JNJ, ABBV, UNH, and MRK — followed by TMO, AMGN, GILD, ABT, and PFE. The fund is passively managed with a full replication strategy, charges a 0.08% expense ratio, and launched in 1998. Its concentration is notable: the top 10 holdings represent roughly 60% of assets, giving mega-cap pharmaceuticals and equipment makers outsized influence over performance and relative positioning.
Both funds operate within a health care sector shaped by several durable catalysts. Weight-loss and metabolic therapies have propelled a handful of large pharmaceutical leaders, while an aging U.S. population sustains structural demand for health care providers, insurers, and medical devices. Innovation in oncology and immunology continues to drive pipeline value, even as drug-pricing scrutiny and policy debate create periodic volatility. Interest-rate expectations matter as well: lower rates tend to support valuations of long-duration biotech and life sciences companies. Sector risks include regulatory changes, patent expirations, and reimbursement pressure, all of which can weigh on earnings cycles for top holdings across both portfolios.
Because their top 10 holdings overlap heavily, VHT and XLV have historically moved in close tandem over recent market cycles, with differences driven primarily by concentration and small-cap exposure. XLV's heavier mega-cap weighting amplifies the influence of the largest pharmaceutical names, which can boost relative returns when mega-cap leadership is strong. VHT's inclusion of mid- and small-cap health care companies provides broader participation when smaller biotech and medical technology names rally, while also adding modest volatility. In recent weeks and months, both funds have reflected the same sector-level rotation, with relative positioning shaped more by concentration than by cost or tracking methodology.
Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics, making it easier to identify trade ideas, trending names, breakout candidates, and market opportunities more efficiently than manual screening. Whether you are comparing sector funds or hunting for emerging opportunities, the AI Screener can help you narrow the field with speed and precision.
Based on observable structural factors, Tickeron's AI would likely favor VHT over XLV at present. While XLV offers a marginally lower expense ratio and deeper liquidity, VHT's roughly 420-stock portfolio delivers substantially broader sector exposure and meaningfully lower single-stock concentration. For investors seeking diversified, all-cap health care access with comparable cost and trend consistency, VHT's wider net reduces idiosyncratic risk while still capturing the sector's dominant mega-cap leaders. The cost difference of one basis point is negligible, making VHT's diversification breadth the deciding factor in this comparison.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where VHT declined for three days, in 243 of 300 cases, the price declined further within the following month. The odds of a continued downward trend are 81%.
The 10-day RSI Indicator for VHT moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 36 similar instances where the indicator moved out of overbought territory. In 27 of the 36 cases, the stock moved lower in the following days. This puts the odds of a move lower at 75%.
The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VHT as a result. In 64 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 72%.
The Moving Average Convergence Divergence Histogram (MACD) for VHT turned negative on November 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 34 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 76%.
VHT moved below its 50-day moving average on November 20, 2026 date and that indicates a change from an upward trend to a downward trend.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The 10-day moving average for VHT crossed bullishly above the 50-day moving average on October 16, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 77%.
Following a +0.36% 3-day Advance, the price is estimated to grow further. Considering data from situations where VHT advanced for three days, in 254 of 312 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
VHT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 200 of 251 cases where VHT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 80%.
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where XLV declined for three days, in 250 of 308 cases, the price declined further within the following month. The odds of a continued downward trend are 81%.
The 10-day RSI Indicator for XLV moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 37 similar instances where the indicator moved out of overbought territory. In 27 of the 37 cases, the stock moved lower in the following days. This puts the odds of a move lower at 73%.
The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on XLV as a result. In 72 of 99 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 73%.
The Moving Average Convergence Divergence Histogram (MACD) for XLV turned negative on November 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 38 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 78%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The 10-day moving average for XLV crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 77%.
Following a +0.33% 3-day Advance, the price is estimated to grow further. Considering data from situations where XLV advanced for three days, in 264 of 325 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
XLV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 225 of 273 cases where XLV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 82%.
| VHT | XLV | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 75% | 3 days ago 73% |
| Stochastic ODDS (%) | 3 days ago 74% | 3 days ago 84% |
| Momentum ODDS (%) | 3 days ago 72% | 3 days ago 73% |
| MACD ODDS (%) | 3 days ago 76% | 3 days ago 78% |
| TrendWeek ODDS (%) | 3 days ago 79% | 3 days ago 78% |
| TrendMonth ODDS (%) | 3 days ago 81% | 3 days ago 81% |
| Advances ODDS (%) | 12 days ago 81% | 12 days ago 81% |
| Declines ODDS (%) | 3 days ago 81% | 3 days ago 81% |
| BollingerBands ODDS (%) | 3 days ago 71% | 3 days ago 76% |
| Aroon ODDS (%) | 3 days ago 80% | 3 days ago 82% |
A.I.dvisor indicates that over the last year, XLV has been closely correlated with LLY. These tickers have moved in lockstep 76% of the time. This A.I.-generated data suggests there is a high statistical probability that if XLV jumps, then LLY could also see price increases.
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| NXUS | 24.48 | 0.10 | +0.39% |
| NuShares ETF Trust Nuveen International Aggregate Bond ETF (NXUS) | |||
| FDRS | 23.94 | N/A | N/A |
| Founder-Led ETF | |||
| BUCK | 23.06 | -0.04 | -0.17% |
| Simplify Treasury Option Income ETF (BUCK) | |||
| DSMC | 42.31 | -0.63 | -1.46% |
| Distillate Small/Mid Cash Flow ETF (DSMC) | |||
| RBLD | 78.83 | -2.36 | -2.91% |
| First Trust Alerian US NextGen Infrastructure ETF (RBLD) | |||